Micrus Corp.

Micrus hopes to break into the underpenetrated market of minimally invasive treatments for cerebral aneurysms with a microcoil that has, it claims, performance characteristics that are superior to Target Therapeutics' Guglielmi Detachable Coil.

Acute stroke represents a virtually unmet clinical need and a tremendous market opportunity. In the US, about 700,000 strokes occur each year, 80% of which are due to occluded vessels (ischemic stroke); the rest are caused by ruptured arteries leading to or within the brain (hemorrhagic stroke). While dozens of start-up companies are staking out claims in the unknown territory of ischemic stroke, Micrus Corp. deliberately sought out technology to treat the cerebral aneurysms and arteriovenous malformations that can cause hemorrhagic stroke. The company hopes to broaden a market created by Target Therapeutics Inc. (now part of Boston Scientific Inc.) with its Guglielmi DetachableCoil, the only FDA approved device for the minimally-invasive treatment of aneurysms. Although it is the only minimally invasive alternative, the GDC is still only used in 5% of patients; the open craniotomy and surgical clipping are still the gold standard for treating cerebral aneurysms. Micrus hopes to break into this existing but underpenetrated market with a new microcoil that has, it claims, performance characteristics that are superior to the GDC.

The goal of these devices is to fill and block an aneurysm, a balloon-like enlargement in a weak vessel wall, sealing it off from blood flow in order to prevent...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.   

Shape Our Content: Take The Reader Survey

 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

In Partnership with Cerba Research

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

More from In Vivo

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By 

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By 

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.

UK Bets On Regulatory Innovation As Competitive Advantage In Synthetic Biology

 
• By 

The UK government has prioritized synthetic biology and created a "concierge service" for biotechs just as the US cuts science funding.